title: Replaced platelet concentrates containing a new additive solution, M-sol: safety and efficacy for pediatric patients.
abstract: BACKGROUND
  Allergic transfusion reactions (ATRs), particularly those caused by plasma-rich platelet concentrates (P-PCs), are an important concern in transfusion medicine. Replacing P-PCs with PCs containing M-sol (M-sol-R-PCs) is expected to prevent ATRs. However, this has not yet been verified by sufficient clinical evidence.
  
  
  METHODS
  A retrospective cohort study was performed between 2008 and 2011. Pediatric patients with hematologic disorders, solid tumors, primary immunodeficiency disorders, or inherited metabolic disorders were transfused with M-sol-R-PCs between 2010 and 2011; the transfusions of P-PCs administered between 2008 and 2011 were compared in terms of frequency and severity of ATRs, corrected count increment (CCI), and occurrence of bleeding. Data were collected for 6 consecutive months on a per-patient basis.
  
  
  RESULTS
  Data obtained during 2008 to 2011 showed that of the 78 patients receiving 515 P-PC transfusions, 14 (17.9%) had 17 ATRs (3.3%); 14 and three ATRs were of Grades 1 and 2, respectively. In 2010 to 2011, 49 patients received 620 transfusions of M-sol-R-PCs, and two patients (4.1%) had Grade 1 ATRs (0.3%). Thus, the frequency of ATRs per bag and per patient differed significantly between the two transfusions. No steroid agents were used for the prevention or treatment of ATRs in the M-sol-R-PC group. The CCI (24 hr) for M-sol-R-PCs did not differ from that for P-PCs.
  
  
  CONCLUSIONS
  M-sol-R-PCs were found to be effective in preventing ATRs without loss of transfusion efficiency in children; however, its efficacy should be further evaluated in prospective clinical trials.
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan; Division of Blood Transfusion, Shinshu University Hospital, Matsumoto, Japan; Hokkaido Red Cross Blood Center, Sapporo, Japan; Department of Pediatrics, Asahikawa Medical University School of Medicine, Asahikawa, Japan.
authors.forename: Ryu
authors.initials: R
authors.lastname: Yanagisawa
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Shimodaira
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kojima
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Nakasone
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Ishikawa
authors.forename: Kayo
authors.initials: K
authors.lastname: Momose
authors.forename: Takayuki
authors.initials: T
authors.lastname: Honda
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: Shoji
authors.initials: S
authors.lastname: Saito
authors.forename: Miyuki
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yozo
authors.initials: Y
authors.lastname: Nakazawa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Sakashita
authors.forename: Masaaki
authors.initials: M
authors.lastname: Shiohara
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Akino
authors.forename: Junichi
authors.initials: J
authors.lastname: Hirayama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Azuma
authors.forename: Kenichi
authors.initials: K
authors.lastname: Koike
mesh_terms: D000293:Adolescent; D001792:Blood Platelets / Q000737:chemistry*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D017713:Platelet Transfusion / Q000009:adverse effects* / Q000379:methods*; D012189:Retrospective Studies